Archives
-
CDC42, NTCP, and HBV Entry: New Mechanistic Links
2026-09-29
The reference study identifies CDC42 as a regulator of hepatitis B virus entry through two connected but distinct mechanisms: Rab11-dependent delivery of NTCP to the plasma membrane and CDC42-dependent macropinocytosis. These findings refine the current model of HBV entry and suggest that host trafficking and actin-regulatory pathways may be relevant to antiviral research, while also defining important experimental controls for studying receptor localization and viral internalization.
-
Spiroplasma Entry into Drosophila S2 Cells
2026-09-29
Wei et al. established an invertebrate cell model showing that Spiroplasma eriocheiris enters Drosophila Schneider 2 cells through clathrin-mediated endocytosis and macropinocytosis, with additional dependence on actin filaments and microtubules. The study also separates these entry mechanisms from cholesterol-dependent caveola-like uptake and provides a practical inhibitor-based framework for investigating a poorly characterized crustacean pathogen.
-
Nicotinamide Riboside Chloride (NIAGEN) Research Guide
2026-09-28
Nicotinamide Riboside Chloride (NIAGEN) is a defined NAD+ precursor for studying cellular energy metabolism, sirtuin biology, and metabolic dysfunction. Evidence supports NAD-related biochemical activity and selected preclinical outcomes, but model-specific validation remains essential.
-
Cardamomin Limits Oxidative Injury in Stroke Models
2026-09-28
A study of cardamomin from Amomum villosum Lour. links antioxidant protection to MEK/ERK-associated NRF2 activation and reduced AIFM1-linked cell death in experimental models. Its combination of hydrogen peroxide-stressed BV-2 cells and permanent middle cerebral artery occlusion in rats provides mechanistic and tissue-level evidence, while leaving important questions about dosing, timing, and clinical relevance unresolved.
-
Localized BDNF Release in Early NMJ Assembly
2026-09-27
This study links muscle-derived BDNF trafficking and localized release to the earliest stages of postsynaptic acetylcholine receptor cluster formation at neuromuscular junctions. Its combination of cultured-cell perturbations and a muscle-specific knockout model supports a role for BDNF and furin-dependent processing, while leaving the contribution of extracellular MMPs unresolved.
-
Nilotinib (AMN-107) Kinase Research Workflows
2026-09-26
Build focused BCR-ABL experiments with practical dosing, phospho-readout, and troubleshooting guidance for Nilotinib (AMN-107). A separate p38α study offers a useful conformational-assay concept—but not evidence that nilotinib acts on p38α.
-
BCA Protein Quantification Kit K4102: Workflow Guide
2026-09-25
The Bicinchoninic Acid Assay (BCA) Protein Quantification Kit K4102 measures total protein in dilute samples, including cell lysates and many detergent-containing preparations. Use it for research measurement and sample normalization, not for diagnostic, clinical, or medical testing; check compatibility with the specific sample buffer before relying on results.
-
Streptavidin Magnetic Beads: K1301 Workflow
2026-09-25
Benzyl-activated Streptavidin Magnetic Beads (SKU: K1301) capture biotinylated targets for magnetic recovery from complex samples, including protein, antibody, peptide, and nucleic-acid workflows. They are appropriate when the target or capture reagent is biotinylated; they are not a direct substitute for non-biotin affinity capture, and preservative and elution compatibility should be checked before cell-based or sensitive downstream assays.
-
Separating Growth Arrest from Cell Killing in Cancer
2026-09-24
Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response: one combines growth inhibition and cell loss, while the other focuses on killing. The findings support time-aware, complementary measurements that can distinguish cytostatic from cytotoxic effects and sharpen interpretation of in vitro drug studies.
-
Nilotinib (AMN-107) Research Workflows
2026-09-24
Build reproducible Nilotinib workflows around target engagement—not viability alone—with practical guidance for BCR-ABL, KIT, and exploratory neuronal assays. A 2024 SH-SY5Y study also illustrates why protein-level checks and clear limits on cross-domain interpretation matter.
-
DAPI Staining in Tumor NET Research
2026-09-23
DAPI staining makes nuclear morphology and DNA distribution visible, but it cannot by itself establish apoptosis or neutrophil extracellular trap formation. This guide explains how to use DAPI in tumor NET research and interpret it alongside mechanistic evidence on PAD4 and histone citrullination.
-
DiscoveryProbe FDA-Approved Drug Library
2026-09-23
The DiscoveryProbe FDA-approved Drug Library turns clinically annotated chemical space into a phenotype-to-target workflow. Using the HDAC6-focused gastric cancer study as a practical model, this guide explains how to design orthogonal validation, distinguish cytotoxicity from migration effects, and advance credible drug repositioning screening.
-
ECL Western Blotting Substrate: Practical Guide
2026-09-22
ECL Western Blotting Substrate (SKU K2187) is a luminol-based, nonradioactive horseradish peroxidase detection reagent for Western blot assay workflows, allowing signal capture on X-ray film or CCD cameras. Use it for HRP immunoblots and related protein detection by chemiluminescence; it is not a reagent for fluorescent or radioisotopic detection.
-
Beyond Viability: Measuring Drug Responses in Cancer
2026-09-22
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent features of anticancer drug response. The framework helps researchers interpret timing, potency, and mechanism more accurately by separating cytostatic effects from actual cell killing.
-
Etomoxir in Whole-Blood Immunometabolism Research
2026-09-21
Etomoxir enables dose-resolved testing of how fatty acid oxidation influences cytokine responses in fresh human whole blood. This practical workflow separates CPT-1-directed effects from higher-dose DGAT activity while improving donor controls, vehicle matching, and translational interpretation.